advocacy

PPMD Joins FDA Leadership for Rare Disease Roundtable

On Wednesday, June 3rd, PPMD was invited to participate in a closed roundtable with senior leadership at the U.S. Food and Drug Administration (FDA). The meeting was convened by Amy Comstock Rick, JD, Director of…

Learn More

Community Comes Together on Capitol Hill: A Recap of PPMD’s 2026 Advocacy Conference

Each year, the Duchenne and Becker muscular dystrophy community comes together in Washington, DC with a shared mission: to ensure that the voices of individuals living with Duchenne and Becker and their families are heard…

Learn More

PPMD and FED Announce 2026 Advocacy Leadership Awards Honoring Bipartisan Champions in Congress

PPMD, in partnership with the Foundation to Eradicate Duchenne (FED), is pleased to announce Representative Troy Balderson (OH-12), Senator Susan Collins (ME), Senator Amy Klobuchar (MN), Representative Doris Matsui (CA-07), and Senator Roger Wicker (MS)…

Learn More

Advocates Unite in Washington to Advance Duchenne and Becker Policy, Mark 25th Anniversary of MD-CARE Act

PPMD heads to Capitol Hill today with a group of more than 120 Duchenne and Becker advocates to meet with Congressional leaders during this year’s annual PPMD Advocacy Conference. “Together, our community has secured victories…

Learn More

February 26, 2026

25 Years Later: Reflecting on the 2001 MD-CARE Act Hearing and Where We Are Now

On Thursday, February 26, advocates, clinicians, patient leaders, and policymakers came together for a powerful Senate Special Committee on Aging hearing titled “From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation.” This conversation served as…

Learn More

February 11, 2026

Rare Disease Advocacy Delivers: Major Federal Wins for Duchenne and Becker Community

We applaud a major legislative victory for the rare disease and Duchenne and Becker community — one made possible because advocates like you raised your voices, shared your stories, and sustained pressure on lawmakers. With…

Learn More

Budget Reconciliation Update and the Impact on Medicaid

PPMD is closely monitoring the U.S. House of Representatives Energy and Commerce Committee markup of the Committee’s budget reconciliation text, scheduled for tomorrow, Tuesday, May 13, 2025, at 2:00 PM ET. Updated legislative language released…

Learn More

Watch: Duchenne Newborn Screening – Next Steps Following ACHDNC Dissolution (Webinar Recording)

Last week, PPMD and the Muscular Dystrophy Association provided insights into the current status of the Duchenne nomination to the federal Recommended Uniform Screening Panel (RUSP) for newborn screening following the dissolution of the Advisory…

Learn More

Congress Moves Forward on Medicaid Cuts: What You Need to Know

This week, we received concerning news from Washington: Congress has passed a budget resolution that will require significant cuts to Medicaid—up to $880 billion over 10 years. Congress is still determining the exact scope and…

Learn More

Duchenne Secures $12.5 Million in CDMRP Funding for FY25: A Hard-Fought Victory in a Challenging Year

We are humbled and grateful to share that Duchenne muscular dystrophy has been recommended by House and Senate Defense Appropriations leadership for $12.5 million in federal funding for Fiscal Year 2025 (FY25) through the Congressionally…

Learn More

Join Our Mailing List